Significant reduction in immunosuppression load on uveitis pts with long term ADA use.#ACR17 @RheumNow
#1115 pic.twitter.com/YM2HM0d9sz— Julio Gonzalez (@japaoli19) November 6, 2017
Japanese study describes top infections in GPA: bacterial PNA, CMV, HZ #1778 #ACR17 @RheumNow @HealioRheum pic.twitter.com/R31p0einP0
— Cassandra Calabrese (@CCalabreseDO) November 6, 2017
Cimzia placental transfer #ACR17 @RheumNow pic.twitter.com/fvM3C9LZKG
— Philip Robinson (@philipcrobinson) November 6, 2017
#GAMECHANGER Leflunomide may be OK in pregnancy if pt is exposed Safe in a large case series #acr17 @rheumnow #1311 pic.twitter.com/HAKmJFTSRL
— Janet (@Janetbirdope) November 6, 2017
Inflammatory arthritis 1 day after nivolumab in pt w/remote +ACPA. Checkpoint inhibitors triggering autoimmunity? @RheumNow #ACR17 pic.twitter.com/OIUSOhAEf7
— Cassandra Calabrese (@CCalabreseDO) November 6, 2017
Oral corticosteroids increase risk of preterm birth in all trimesters (regardless DMARD exposure)#ACR17 @rheumnow #1313
— Dr. Paul Sufka (@psufka) November 6, 2017
Seoul RCT: MTX discontinuation for 2 weeks after flu vaccine increased satisfactory vaccine response. No difference in flares #ACR17 #RA pic.twitter.com/6b4i01KjI4
— Trudy Taylor (@HalifaxRheum) November 5, 2017
Etanercept pregnancy update.FDA Year in Review session. #ACR17 >FB pic.twitter.com/oVTFiiehAZ
— ARD (@ARD_BMJ) November 6, 2017
No difference in outcomes compared to baseline for pts exposed to certolizumab during 1st tri of pregnancy #ACR17 @rheumnow #1309 pic.twitter.com/l9ABG7B8A7
— Dr. Paul Sufka (@psufka) November 6, 2017
Bingham: “birth & genesis of a completely new disease” – checkpoint inhibitor-induced rheumatic disease #ACR17 @rheumnow
— Dr Irwin Lim (@_connectedcare) November 5, 2017
Treatment of IRAEs has really been steroids & a few other Dmards #ACR17 @rheumnow pic.twitter.com/mzHoYHAPRt
— Dr Irwin Lim (@_connectedcare) November 5, 2017
GCA roughly doubles Coronary risk, VTE risk, stroke risk #acr17 @RheumNow
— Dr Irwin Lim (@_connectedcare) November 6, 2017
RT @RheumNow: Risk of 2nd (recurrence) cancer after a 1st cancer is not increased with biologic use. #ACR17 Abs 11L pic.twitter.com/GMQVyXxZEh
— Dr Irwin Lim (@_connectedcare) November 6, 2017
#Biologic use during pregnancy may not increase opportunistic infection risk in infants. Press release: https://t.co/VCkbXno65Q #ACR17
— AmerCollRheumatology (@ACRheum) November 6, 2017
FDA issues strong warnings: no codeine/tramadol during pregnancy/breastfeeding due to risk to infants #ACR17 @rheumnow pic.twitter.com/qIap9J3C2L
— k dao (@KDAO2011) November 6, 2017
Canadian cohort: Possible risk for preterm delivery w/DMARD exposure preconception and pregnancy #ACR17 @rheumnow #362 pic.twitter.com/f6k2QmxFnD
— k dao (@KDAO2011) November 6, 2017
#GAMECHANGER pts trust rheums and agree 97% of time to take new Rx but fill script 2/3 of time #acr17 @rheumnow #1385 pic.twitter.com/DEGlwvgeop
— Janet (@Janetbirdope) November 6, 2017
#GAMECHANGER TNFI gives more ILD in RA than Abatacept in one study and not in another Not sure why. #acr17 @rheumnow #137 #526
— Janet (@Janetbirdope) November 6, 2017
FDA updates. New approvals/indications #ACR17 @rheumnow pic.twitter.com/E89GndAsbf
— k dao (@KDAO2011) November 6, 2017
Secukinumab meets T2T endpoints in PsA.Early onset did better. Should we measure in clinic?#ACR17 @RheumNow #622 pic.twitter.com/SchOSRVqKT
— Julio Gonzalez (@japaoli19) November 6, 2017
#1173 rheumatic irAEs more common w/combo anti-PD-1/CTLA-4 and assoc w/response to cancer Tx @RheumNow @HealioRheum #ACR17 pic.twitter.com/0TkDoqsV1W
— Cassandra Calabrese (@CCalabreseDO) November 6, 2017
CMV and herpes zoster appear to have an increased risk in JAK inhibitors- other opportunistic infections also reported #acr17 c/o Winthrop pic.twitter.com/NRcskpfGlx
— ARD (@ARD_BMJ) November 6, 2017
HCQ levels drop in pregnancy – optimizing dosing for improved maternal/fetal outcomes. #ACR17 @RheumNow #1296 https://t.co/jMOW9XmBKB pic.twitter.com/YqnPjzKShP
— Dr. Rachel Tate (@DrRachelTate) November 6, 2017
Risk of a 2nd (recurrence) cancer after a 1st cancer is not increased with biologic use. #ACR17 Abstr 11L pic.twitter.com/kjWnAK2QN4
— Dr. John Cush (@RheumNow) November 6, 2017
Maternal #biologic use did not increase risk for opportunistic infections in #newborns https://t.co/1Iaj1awDK0 #ACR17 pic.twitter.com/3GGIYVu5Bw
— Healio Rheumatology (@HealioRheum) November 6, 2017
Large trial, long fu. Celecoxib does NOT cause more CVS issues than Naproxen or Ibuprofen #ACR17 @rheumnow pic.twitter.com/mszgPO3P0D
— Dr Irwin Lim (@_connectedcare) November 5, 2017
More long term safety data with Biologics in this abstract looking at infections in long term users in Latin America #ACR17 @rheumnow #541 pic.twitter.com/HsIAzEymBw
— William Shergy (@WShergy) November 5, 2017
Dr. Jack Cush: Plenary Session on Bisphosphonate Holiday
The reason why Etoricoxib is preferred NSAID in #AnkylosingSpondylitis #ACR17 @RheumNow pic.twitter.com/gbit47We7n
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
Super excited about this talk on checkpoint inhibitor immune mediated disease #ACR17 pic.twitter.com/E58KSa3T6k
— Philip Robinson (@philipcrobinson) November 5, 2017
PD1/PDL1 checkpoint helps turn OFF T-cells
Cancer cells can express PDL1. Many tumours are “PDL-omas” #acr17 @RheumNow— Dr Irwin Lim (@_connectedcare) November 5, 2017
ARCH study romosozumab vs alendronate 48% RRR vertebral fx and 38% RRR hip fx w/romo at 2 yrs #ACR17 @rheumnow #318 pic.twitter.com/jPNIqRNuRN
— k dao (@KDAO2011) November 5, 2017
Clifton O. Bingham III: Many potential immunologic checkpoint targets for therapies = more IRAEs! @RheumNow #ACR17 pic.twitter.com/cXLQVDM1I9
— Cassandra Calabrese (@CCalabreseDO) November 5, 2017
Vaccination of juvenile SLE w/ hepA vaccine won’t flare SLE and still garner good response #ACR17 @rheumnow #369
— k dao (@KDAO2011) November 5, 2017
Multiple immune related adverse events over different time points may occur with Checkpoint Inhibitors #ACR17 @rheumnow pic.twitter.com/MjtbfCMmgx
— Dr Irwin Lim (@_connectedcare) November 5, 2017
Blacks and Asians more likely to die from infx and whites more likely from CV and neoplasms
— k dao (@KDAO2011) November 5, 2017
Here’s a list of COMMON malignancies in Dermatomyositis #ACR17 @rheumnow pic.twitter.com/mEmJPOm7fh
— Dr Irwin Lim (@_connectedcare) November 5, 2017
We must educate Rheumatologists on rheumatic IRAE from checkpoint! #116 #ACR17 @cappelliMD @RheumNow @LCalabreseDO pic.twitter.com/CPf26tEqF5
— Cassandra Calabrese (@CCalabreseDO) November 5, 2017
Switching to non-TNF bDMARDs more effective than cycling 2nd line TNFi bDMARDs in TNF-IR pts. #ACR17 @RheumNow #238 https://t.co/RUGisVifAD pic.twitter.com/Q2Ps41CTVR
— Dr. Rachel Tate (@DrRachelTate) November 5, 2017
Dr. Kathryn Dao: Early Arthritis
Higher remission rates and lower steroid dose with tocilizumab in GCA. Year in review #ACR17 @RheumNow pic.twitter.com/nRq6DReg9H
— Olga Petryna (@DrPetryna) November 5, 2017
Biologic&non-biologic DMARDs don’t increase infection risk in pregnancy, steroids do #acr17 #YearInReview @RheumNow pic.twitter.com/dNPbdN99Ce
— Olga Petryna (@DrPetryna) November 5, 2017
Risk of fx also increase w/ > 1 yr bisph holiday (10-20%)
— k dao (@KDAO2011) November 5, 2017
#ACR17 methotrexate: better subcutaneous than oral. A meta-analysis pic.twitter.com/2nlvmayFOs
— Dr. Juan Ovalles (@DrJuanOvalles) November 5, 2017
CHIKv infection leading to de novo rheumatic conditions, risk incr if RF or CCP+ #277 #ACR17 @RheumNow @HealioRheum
— Cassandra Calabrese (@CCalabreseDO) November 5, 2017